Literature Review of 141 Cases of Adverse Drug Reactions Induced by Simvastatin

Abstract

Abstract: Objective To provide references for the safe and rational use of simvastatin in clinic through investigating the characteristics of adverse drug reactions (ADRs) induced by this drug. Methods Using "simvastatin", "adverse reaction" as key words to search and retrieve articles in the CNKI database, WanFang database and VIP Chiese full-text database. The literature was analyzed according to the inclusion and exclusion criteria. Results A total of 123 papers, 141 cases were included. Systems and organs mainly involved in ADRs were musculo-skeletal system disorders and liver and biliary system disorders. ADRs occurred most frequently within 90 days of medication. Conclusion It is important for clinicians and patients to make aware of simvastatin-induced ADRs. Supervision and precaution should be strengthened in the clinical use of simivastatin.

Key words: simvastatin, adverse drug reactions, literature review

CLC Number:

R994.11

ZHANG Xuan, GU Yunxia*. Literature Review of 141 Cases of Adverse Drug Reactions Induced by Simvastatin[J]. Chinese Journal of Pharmacovigilance, 2019, 16(8): 487-491.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/

https://zgywjj.magtechjournal.com/EN/Y2019/V16/I8/487

References

[1] Rosenson R S, Baker S K, Jacobson T A, et al.An assessment by the Statin Muscle Safety Task Force: 2014 update[J]. Journal of Clinical Lipidology, 2014, 8(3):S58-S71.
[2] 高千秋, 张浩嘉. 302例他汀类药物相关肌肉系统损害的文献分析[J]. 中国药物警戒, 2018, 15(8):476-480.
[3] 国家药品不良反应监测中心. 药品不良反应报告和监测工作手册[EB/OL]. (2012-11)[2019-04-22]. http://www.cdr-adr.org.cn/xzzx/hyzl/hyzl2013nd/201304/t20130426_5436.html.
[4] 刘晓凯. 辛伐他汀致肌病及急性肾功能不全一例报告[J].浙江临床医学, 2006,8(1): 85.
[5] 杜娟. 辛伐他丁致横纹肌溶解综合征1例[J].中国临床药学杂志, 2011, 20(6): 378.
[6] 金旭明, 刘翠芹.辛伐他汀致严重肝脏损害久治不愈一例[J].中国疗养医学, 2011. 20(7): 655.
[7] 林玳. 辛伐他汀与环孢素合用引起横纹肌溶解案例分析[C]//2012年浙江省医学会临床药学学术年会暨医院药事管理质控中心.临床药学分会十周年庆典大会论文集. 杭州:2012:462-464.
[8] 中国老年医学研究会内分泌代谢分会, 中国毒理学会临床毒理专业委员会. 老年人多重用药安全管理专家共识[J]. 中国药物警戒, 2018, 15(10):55-68.
[9] 国家药品监督管理局药品评价中心. 警惕辛伐他汀与胺碘酮联合使用或高剂量使用增加横纹肌溶解发生风险[EB/OL]. (2010-11-16)[2019-03-29]. http://samr.cfda.gov.cn/WS01/CL1989/55959.html.
[10] FDA. Drug Safety Communication: New restrictions, contraindications,dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury[EB/OL]. (2011-06-08)[2019-03-29]. https://www.fda.gov/Drugs/DrugSafety/ucm256581.htm.
[11] Francois Mach, Kausik K Ray, Olov Wiklund, et al.Adverse effects of statin therapy: perception vs. the evidence -focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract[J]. European Heart Journal, 2018, 39(27): 2526-2539.
[12] 诸骏仁, 高润霖, 赵水平, 等. 中国成人血脂异常防治指南(2016年修订版)[J]. 中国循环杂志, 2016, 16(10):15-35.
[13] Sakamoto K, Kimura J.Mechanism of Statin-Induced Rhabdomyolysis[J]. Journal of Pharmacological Sciences, 2013, 123(4):289-294.
[14] 李昂, 张冰, 张晓朦, 等. 1109所基层医疗机构的药品不良反应认知及呈报情况调研[J]. 中国药物警戒, 2017. 14(5):289-294.

[1]	LI Mingying, ZHANG Xiaoxia, SUN Xiaoli, ZHAO Yan, HE Miao, LI Yanling, DUAN Wei, YANG Ou. Effect of Sugammadex on Recovery of Patients after Laparoscopic Total Pelvic Floor Reconstruction [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 896-901.
[2]	KE Xiuqin, HAI Xuewu. 433 Cases of Adverse Drug Reactions Induced by Calcium Dobesilate Capsules [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 924-927.
[3]	LIANG Jie. 172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932.
[4]	YANG Xin, YANG Baochun, YANG Yang, SHAO Huan. One Case of Multiple Endocrine Adverse Effect Caused by Sintilimab [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 947-949.
[5]	WANG Chunting, CHEN Yafei. Considerations for Revision of Safety Information in the Post-Marketing Instructions of Chemical Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 776-779.
[6]	ZHU Huijuan, REN Jingtian. Safety Risks of Human Rabies Immunoglobulin [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 786-789.
[7]	CHEN Yaozhe, ZHAN Yunli, SONG Xingdong, ZHU Manyu, OU Xuemei, LI Chuyun. 48 Cases of Hematological Adverse Reactions Associated with Piperacillin Sodium and Tazobactam Sodium [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 794-798.
[8]	LEI Jianlin, WANG Na, WANG Wenzheng, WANG Yan. One Case of Phenytoin Intoxication Caused by Compound Phenytoin Sodium Ephedrine Hydrochloride and Theophylline Tablets [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 819-822.
[9]	ZHONG Xinru, YANG Deying, GUAN Tangming, CHEN Ju, JIANG Dongbo. Research Progress in Adverse Reactions Caused by Obinutuzumab in the Treatment of Follicular Lymphoma [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 831-835.
[10]	ZHU Lei, ZHANG Xian, WANG Ruiyan, LI Ying. Adverse Reactions Reports about Tislelizumab Injection in 447 Cases [J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 649-653.
[11]	FU Weiran, ZOU Dongmei, NI Jing, SUN Wanling, GUO Yixian. Short-Term Efficacy and Safety of Thiotepia-based Conditioning Regimen Combined with Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Primary Central Nervous System Lymphoma [J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 664-668.
[12]	SUN Zhonghui, LIU Yingchun, DONG Qi, ZHANG Qian, YANG Jing. One Case of Drug Hypersensitivity Syndrome Caused by Hydroxychloroquine Sulfate Tablets [J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 689-692.
[13]	TAO Xingru, DUAN Yanyan, LIU Xiaoling, LIU Yuemei, ZHANG Shengnan. One Case of Black Hairy Tongue Caused by Doxycycline [J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 696-698.
[14]	YAN Caiying, QIN Linying, XU Yaoqing, WANG Xinge, CHAI Nannan, CHEN Long. Research Progress in Uric Acid-Lowering Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 592-595.
[15]	LIU Ying, GUO Hongye, YANG Yiheng, JIN Rui. One Case of Hematological Abnormalities Caused by Lipoic Acid Injection [J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 456-459.